Kerbside
The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Therefore we advise readers to use their own discretion before investing in these recommendation
FINDING PEACE IN DIFFICULT TIMES
Cipla
BSE Code: 500087
CMP: Rs946.60
With the country now gripped in the tentacles of a second wave of the corona virus, pharmaceutical stocks are back into reckoning. One of the preferred bets within this sector by a leading technical analyst is Cipla. As per him, the stock has resumed its uptrend after consolidating above the recent breakout area. Furthermore, he states that Cipla was seen losing its relative momentum while staying in the leading quadrant. However, over the last two weeks, it has appeared to have improved on its relative momentum front. This stock is likely to continue outperforming the pharmaceutical index. It’s a good stock to add to your portfolio when the market is otherwise looking bleak and depressing.
STRIKE WHILE THE IRON IS HOT
Subex
BSE Code: 532348
CMP: Rs52.50
Subex is a pioneer in the space of digital trust, providing solutions for 75 per cent of the world’s top 50 telecom companies. Today, it is a consultant to global telecom carriers for operational excellence and business transformation by driving new revenue models, enhancing the customer experience and optimizing the enterprise. The stock’s relative strength rating is as high as 99, which is great and indicates outperformance as compared to the other stocks. Its master score of B is close to being the best. Momentum traders can enter this stock for short-term gains; however, it’s important to keep a stop loss as it’s a high-risk pick.
PERFECT REMEDY FOR YOUR PORTFOLIO
Indoco Remedies
BSE Code: 532612
CMP: Rs319.40
indoco Remedies is a fully integrated, research-oriented pharmaceutical company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company has been present for more than seven decades in the Indian pharmaceutical market and commands a strong foothold in the international market across 55 countries. From a technical standpoint, the stock is comfortably placed above its key moving averages like 50 and 200 DMA. The stock is currently forming a base in its weekly chart and is just 6 per cent away from the crucial pivot point. It’s a good stock to accumulate.
WORTH A FORTUNE
SRF
BSE Code: 503806
CMP: Rs6234.65
SRF Limited is a multi-business chemicals conglomerate engaged in the manufacturing of industrial and specialty intermediates. The company’s business portfolio covers fluorochemicals, specialty chemicals, packaging films, technical textiles, coated and laminated fabrics. The stock is up by 15 per cent on month-till-date basis and on a year-to-date basis it is up in double digits. Recently, the stock has witnessed breakout of Stage 2 consolidation pattern and is meeting most of the criteria of CANSLIM methodology. Hence, it can be bought for handsome gains.
(Closing price as of April 19, 2021)